Innovent Biologics, Inc. (1801.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: De-Chao Yu
Listed since: Oct 31, 2018
Employees: 7,502

Market position

Day range

Current HK$99.50

HK$98.55HK$103.3

52-week range

Current HK$99.50

HK$69.55HK$109.1

Open: HK$103.2
Previous close: HK$102.4
Volume: 10.83M; 0.78× average
Average volume: 13.91M; Average daily volume
Market cap: 173.22B HKD
Beta: 0.23; Market reference 1
50-day average: HK$87.78; +13.35% above average
200-day average: HK$85.9055; +15.82% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 104.02B CNY
EV / EBITDA: 79.39×
Earnings yield: 0.69%
Free cash flow yield: 7.86%

Profitability & efficiency

Return on equity: 4.20%
Return on assets: 2.18%
Return on invested capital: 2.39%

Financial health

Current ratio: 2.62×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

13.04B CNY+38.42%

Operating income

733.62M CNY+1.49B CNY

Net income

813.57M CNY+908.2M CNY

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	13.04B CNY	9.42B CNY	6.21B CNY	4.56B CNY	4.27B CNY
Cost of goods sold	3.04B CNY	1.51B CNY	1.81B CNY	930.99M CNY	573.04M CNY
Gross profit	10B CNY	7.91B CNY	4.4B CNY	3.63B CNY	3.7B CNY
Research and development	2.62B CNY	2.68B CNY	2.23B CNY	2.87B CNY	2.48B CNY
Selling, general, and administrative	6.64B CNY	5.08B CNY	3.85B CNY	3.43B CNY	3.61B CNY
Operating expenses	9.26B CNY	7.65B CNY	6.08B CNY	6.21B CNY	5.75B CNY
Interest income	427.33M CNY	423.45M CNY	452.84M CNY	189.54M CNY	151.76M CNY
Interest expense	77.54M CNY	67.65M CNY	98.62M CNY	101.7M CNY	62.46M CNY
Depreciation and amortization	576.53M CNY	275.6M CNY	385.1M CNY	319.42M CNY	204.75M CNY
Operating income	733.62M CNY	−755.87M CNY	−1.68B CNY	−3.12B CNY	−2.7B CNY
Net income	813.57M CNY	−94.63M CNY	−1.03B CNY	−2.18B CNY	−2.73B CNY